Internal Reference Number: FOI_6331
Date Request Received: 20/10/2021 00:00:00
Date Request Replied To: 17/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Treatment for colorectal cancer
Request Category: Researcher
Question Number 1: Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]? • Aflibercept • Bevacizumab • Capecitabine • CAPIRI • CAPOX (XELOX) • Cetuximab in combination with FOLFIRI • Cetuximab in combination with FOLFOX • Cetuximab not in combination with FOLFIRI or FOLFOX • Irinotecan only • FOLFIRI • FOLFOX • Fluorouracil (5FU) only • Oxaliplatin only • Panitumumab in combination with FOLFIRI • Panitumumab in combination with FOLFOX • Panitumumab not in combination with FOLFIRI or FOLFOX • Pembrolizumab • Nivolumab • Raltitrexed • Ramucirumab • Regorafenib • Sorafenib • Other SACT | |
Answer To Question 1: Aflibercept, bevacizumab, CAPIRI, Cetuximab with FOLFIRI, irinotecan only and the one with oxaliplatin, fluorouracil, oxaliplatin only, panitumumab not in combination, nivolumab, ramucirumab, regorafenib and sorafenib all zero Capecitabine -7 CAPOX 27 Cetuximab not in combination with FOLFOX or FOLFIRI- 2 patients FOLFIRI- 7 FOLFOX- 14 Panitumumab with FOLFIRI- 3 Panitumumab with FOLFOX- 1 Pembrolizumab- 2 Raltirexed- 1 Unable to supply data for for Other SACT as there were too many treatment episodes to filter to estimate the number | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.